A case study of personalized therapy for osteosarcoma

Lara E. Davis, Nicolle E. Hofmann, Guangheng Li, Elaine T. Huang, Marc M. Loriaux, Shay Bracha, Stuart C. Helfand, John E. Mata, Kevin Marley, Atiya Mansoor, Jeffrey W. Tyner, Jinu Abraham, Bernard Séguin, Charles Keller

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Background: Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma. Procedure: Rapid establishment of a primary tumor cell culture is described, followed by efficient functional characterization of the tumor that identified the Src inhibitor dasatinib as the most effective targeted therapy for this individual dog. Results: Adjuvant dasatinib was administered for a total of 26 weeks following treatment with chemotherapy. Pharmacokinetic studies confirm that a therapeutic serum concentration was achieved at a tolerable dose of 0.75mg/kg/day. The canine patient remains without evidence of recurrent disease 24 months following initial diagnosis. Conclusions: The approach described through this illustrative case study is broadly applicable and might be used for other solid tumors in canines as well as in humans.

Original languageEnglish (US)
Pages (from-to)1313-1319
Number of pages7
JournalPediatric Blood and Cancer
Issue number8
StatePublished - Aug 2013


  • Canine
  • Dasatinib
  • Osteosarcoma
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'A case study of personalized therapy for osteosarcoma'. Together they form a unique fingerprint.

Cite this